Why pharmaceutical companies continue investing billions in psychedelic drugs despite regulatory setbacks and unresolved safety questions

Pharmaceutical investment in psychedelic therapies is accelerating despite the FDA’s rejection of MDMA-assisted therapy for post-traumatic stress disorder. Eli Lilly plans to acquire AtaiBeckley for up to $3.8 billion, while AbbVie acquired the short-acting psychedelic bretisilocin for $1.2 billion. Late-stage studies are reporting promising effects for depression and anxiety, including results from LSD- and psilocybin-based treatments, and regulators are issuing clearer guidance on trial design, functional unblinding and clinical infrastructure. Developers are also modifying compounds to shorten psychedelic effects and reduce hallucinations, supervision demands and costs. However, important uncertainties remain around mental and physical adverse effects, therapeutic context, durability and cardiovascular risks. The field’s progress could still be disrupted by regulatory failures or political backlash, echoing earlier setbacks caused by the war on drugs.